Breaking News

Tweet TWEET

Dana-Farber's Belfer Institute for Applied Cancer Science and Evotec Establish Collaboration in Oncology

Dana-Farber's Belfer Institute for Applied Cancer Science and Evotec Establish
Collaboration in Oncology

Collaboration to Discover New Oncology Therapies Targeting Epigenetic
Mechanisms

HAMBURG, Germany and BOSTON, April 30, 2013 (GLOBE NEWSWIRE) -- The Belfer
Institute for Applied Cancer Science at Dana-Farber Cancer Institute and
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN:DE0005664809) today announced a
research collaboration aimed at discovering and commercialising novel cancer
treatments based on epigenetic drug mechanisms.

The goal of the collaboration is to validate emerging epigenetic targets for
oncology indications and to demonstrate the drugability of the selected target
families. Evotec, Dana-Farber and Dana-Farber's Belfer Institute for Applied
Cancer Science will invest in enabling technologies, experimental target
validation and the generation of chemical matter by leveraging existing
expertise and platforms. The collaboration will be fuelled by substantial
scientific contributions from the three organisations aligned on the objective
to develop therapies that address unmet medical needs for cancer patients.

Epigenetics is a rapidly evolving high potential field of pharmaceutical
research, calling for close relationships between academia and biotechnology
innovators. By combining the complimentary capabilities of Dana-Farber, the
Belfer Institute for Applied Cancer Science and Evotec this collaboration is
uniquely positioned to succeed.

"We are very proud to have entered into this collaboration with Dana-Farber
and the Belfer Institute for Applied Cancer Science, which perfectly matches
our innovation strategy as described in Evotec's Action Plan 2016", said Dr
Werner Lanthaler, CEO of Evotec. "We are enthusiastic about exploring novel
targets that have the potential to produce first-in-class therapeutics for the
treatment of cancer."

Dr Jessie English, Head of Research at the Belfer Institute for Applied Cancer
Science, added: "This pioneering partnership provides a unique opportunity to
combine Evotec's drug discovery capabilities with Belfer Institute for Applied
Cancer Science and Dana-Farber Cancer Institute's expertise in oncology
disease biology to accelerate the development of new medicines for patients."

Further details and commercial terms of the cooperation are not disclosed.

ABOUT DANA-FARBER CANCER INSTITUTE

Dana-Farber Cancer Institute (www.dana-farber.org) is a principal teaching
affiliate of the Harvard Medical School and is among the leading cancer
research and care centers in the United States. It is a founding member of the
Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer
center by the National Cancer Institute. It provides adult cancer care with
Brigham and Women's Hospital as Dana-Farber/Brigham and Women's Cancer Center
and it provides pediatric care with Boston Children's Hospital as
Dana-Farber/Children's Hospital Cancer Center. Dana-Farber is the top ranked
cancer center in New England, according to U.S. News & World Report, and one
of the largest recipients among independent hospitals of National Cancer
Institute and National Institutes of Health grant funding. Follow Dana-Farber
on Facebook: www.facebook.com/danafarbercancerinstitute and on Twitter:
@danafarber.

ABOUT EVOTEC AG

Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing the
highest quality stand-alone and integrated drug discovery solutions, covering
all activities from target-to-clinic. The Company has established a unique
position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and expertise
in key therapeutic areas including neuroscience, pain, metabolic diseases as
well as oncology and inflammation. Evotec has long-term discovery alliances
with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen
Pharmaceuticals, MedImmune/AstraZeneca and Ono Pharmaceutical. In addition,
the Company has existing development partnerships and product candidates both
in clinical and pre-clinical development. These include partnerships with
Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes,
with Janssen Pharmaceuticals in the field of depression and with Roche in the
field of Alzheimer's disease. For additional information please go to
www.evotec.com.

ABOUT EPIGENETICS

In biology, and specifically genetics, epigenetics is the study of changes in
gene expression or cellular phenotype, caused by mechanisms other than changes
in the underlying DNA sequence – hence the name epi- (Greek: επί- over, above,
outer) -genetics, some of which are heritable. It refers to functionally
relevant modifications to the genome that do not involve a change in the
nucleotide sequence. Examples of such modifications are DNA methylation and
histone modification, both of which serve to regulate gene expression without
altering the underlying DNA sequence. (Source:Wikipedia.org/wiki/Epigenetics)

FORWARD LOOKING STATEMENTS — Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent the
judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a variety
of risks and uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those contemplated in
these forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in events,
conditions or circumstances on which any such statement is based.

CONTACT: Gabriele Hansen
         Head of Corporate Communications
         +49.(0)40.560 81-255
         +49.(0)40.560 81-222 Fax
         gabriele.hansen@evotec.com
        
         Evotec AG
         Manfred Eigen Campus
         Essener Bogen 7
         22419 Hamburg (Germany)